Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) have climbed more than 130% over the past three months. A significant portion of this gain occurred since early December, following the release of positive data from a study of its oral obesity pill.
A clinical trial tested aleniglipron on obese or overweight patients who also had one or more weight-related co-morbidities. After 36 weeks of treatment at a 120 mg dose, participants demonstrated an average weight loss of 11.3%. The development is notable as the current obesity treatment market is largely dominated by injectable drugs.
The company also reported ongoing research involving a 240 mg dose. This higher dosage yielded a 15.3% average weight loss at the 36-week mark.
On December 17, Structure Therapeutics announced it had initiated the first human trial for ACCG-2671. This is an oral small-molecule amylin receptor agonist also being developed to treat obesity.
Wall Street analysts maintain a bullish stance on the stock. As of the market close on January 12, the consensus rating is Strong Buy, with a one-year average share price target of $104. This target implies a potential upside of 49.94% from recent levels.
Recent analyst actions include LifeSci Capital reiterating a Buy rating on January 6, with a price target of $107. This followed a January 2 update from BMO Capital, which maintained its Outperform rating and set a price target of $130.
Structure Therapeutics Inc. is a biotechnology company focused on developing treatments for chronic metabolic conditions.